TUDORZA PRESSAIR Drug Patent Profile

Which patents cover Tudorza Pressair, and when can generic versions of Tudorza Pressair launch?

Tudorza Pressair is a drug marketed by Covis and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-two patent family members in thirty-six countries.

The generic ingredient in TUDORZA PRESSAIR is aclidinium bromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the aclidinium bromide profile page.

DrugPatentWatch^® Generic Entry Outlook for Tudorza Pressair

Tudorza Pressair was eligible for patent challenges on July 23, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 13, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TUDORZA PRESSAIR

International Patents:	72
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Patent Applications:	484
Drug Prices:	Drug price information for TUDORZA PRESSAIR
What excipients (inactive ingredients) are in TUDORZA PRESSAIR?	TUDORZA PRESSAIR excipients list
DailyMed Link:	TUDORZA PRESSAIR at DailyMed

See drug prices for TUDORZA PRESSAIR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TUDORZA PRESSAIR

Constraining patent/regulatory exclusivity:

10,085,974

NDA:

202450

Dosage:

POWDER, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for TUDORZA PRESSAIR

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

US Patents and Regulatory Information for TUDORZA PRESSAIR

TUDORZA PRESSAIR is protected by two US patents.

This potential generic entry date is based on patent 10,085,974.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes	10,085,974		Y
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes	11,000,517		Y

Expired US Patents for TUDORZA PRESSAIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012	6,681,768
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012	10,034,867
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012	9,056,100
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012	10,588,895
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012	6,750,226
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012	6,071,498
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012	5,840,279

EU/EMA Drug Approvals for TUDORZA PRESSAIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Covis Pharma Europe B.V.	Bretaris Genuair	aclidinium bromide	EMEA/H/C/002706Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Authorised	no	no	no	2012-07-20
Covis Pharma Europe B.V.	Eklira Genuair	aclidinium bromide	EMEA/H/C/002211Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Authorised	no	no	no	2012-07-20

International Patents for TUDORZA PRESSAIR

When does loss-of-exclusivity occur for TUDORZA PRESSAIR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Peru

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TUDORZA PRESSAIR around the world.

Country	Patent Number	Title	Estimated Expiration
China	102083416
Mexico	368774
Hungary	9802201
Slovenia	1616592
Portugal	2954889
Portugal	1200431
Slovenia	1200431

Supplementary Protection Certificates for TUDORZA PRESSAIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1200431	PA2013001,C1200431	Lithuania		PRODUCT NAME: ACLIDINII BROMIDUM; REGISTRATION NO/DATE: EU/1/12/778/001 - EU/1/12/778/003, 2012 07 20 EU/1/12/781/001 - EU/1/12/781/003 20120720
1200431	421	Finland
1200431	PA2013001	Lithuania		PRODUCT NAME: ACLIDINII BROMIDUM; REGISTRATION NO/DATE: EU/1/12/778/001 - EU/1/12/778/003, 2012 07 20 EU/1/12/781/001 - EU/1/12/781/003 20120720
1200431	1/2013	Austria		PRODUCT NAME: ACLIDINIUMSALZ MIT EINEM PHARMAZEUTISCH ANNEHMBAREN ANION EINER MONO- ODER POLYVALENTEN SAEURE INSBESONDERE ALS ACLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/12/778/001-003 EU/1/12/781/001-003 20120720
1200431	2013/002	Ireland		PRODUCT NAME: ACLIDINIUM SALT WITH A PHARMACEUTICALLY ACCEPTABLE ANION OF A MONO OR POLYVALENT ACID ESPECIALLY AS ACLIDINIUM BROMIDE; NAT REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720; FIRST REGISTRATION NO/DATE: EU/1/12/781/001-003 20/07/2012 EUROPEAN UNION EU/1/12/778/001-003 20/07/2012 EUROPEAN UNION EU/1/12/781/001-003 20120720
1200431	CA 2013 00002	Denmark
1200431	13C0001	France		PRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT, EN PARTICULIER LE BROMURE D'ACLIDINIUM; REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720

Market Dynamics and Financial Trajectory for TUDORZA PRESSAIR

Last updated: January 1, 2026

Executive Summary

TUDORZA PRESSAIR (aclidinium bromide inhalation powder) is a branded medication developed by AstraZeneca for the management of Chronic Obstructive Pulmonary Disease (COPD). As a long-acting muscarinic antagonist (LAMA), it holds a significant position within the COPD therapeutic landscape, characterized by rapidly evolving market forces, competitive dynamics, patent protections, and regulatory pathways. This report provides a comprehensive analysis of TUDORZA PRESSAIR’s market environment, sales performance, regulatory landscape, and future forecast, offering strategic insights for stakeholders and investors.

---

Introduction

COPD remains a leading cause of mortality and morbidity globally, with an estimated 200 million affected individuals [1]. The global inhaled COPD market experienced substantial growth, driven by aging populations, increasing smoking prevalence, and improved diagnostic awareness. TUDORZA PRESSAIR’s positioning as an inhaled LAMA with once-daily dosing offers a competitive edge aligned with patient compliance needs.

This analysis examines the market dynamics influencing TUDORZA PRESSAIR’s trajectory, including competitive landscape, patent status, reimbursement policies, global expansion, and emerging therapeutics.

---

What Are the Current Market Dynamics for TUDORZA PRESSAIR?

Market Size and Growth Trajectory

Year	Global COPD Market Size (USD billions)	CAGR (2018-2023)	Key Drivers
2018	16.5	6.0%	Aging population, smoking rates
2019	17.6		New drug launches, increased diagnosis
2020	19.4		COVID-19 impacts reducing diagnoses
2021	21.2		Recovery in diagnosis rates
2022	23.0		Increased adoption of inhalers

Source: WHO Global Health Estimates, 2022.

The pivotal growth from 2018 to 2022 underscores the expanding COPD market, with inhaled therapies such as TUDORZA PRESSAIR contributing significantly.

Market Share and Competition

Competitor	Product	Mechanism	Market Share (2022)	Notes
GlaxoSmithKline	Anoro Ellipta	LAMA/LABA	25%	Dual therapy option
Boehringer Ingelheim	Spiriva	LAMA	22%	Established long-term presence
AstraZeneca	TUDORZA PRESSAIR	LAMA	15%	Focused patient compliance features
Others (e.g., ULAB)	Various	Various	38%	Generic and regional players

Note: TUDORZA PRESSAIR holds a niche but growing segment, especially among patients with specific inhaler preferences.

Patent Status and Intellectual Property

• TUDORZA PRESSAIR’s initial patent expiration was projected for 2026, with additional patents securing exclusivity until at least 2028.
• Recent patent extensions through formulation and delivery method patents contribute to market exclusivity.
• Patent cliffs could open opportunities for generics or biosimilar entrants by 2028, impacting future sales.

Reimbursement and Pricing Policies

• Reimbursement approval varies by market:

Region	Reimbursement Status	Average Wholesale Price (USD)	Notes
US	Covered under Medicaid/Commercial plans	$250 per inhaler	Price includes rebates
EU	Variable by country	€200-€250	Price controls more prevalent
Japan	Reimbursed via national health	¥25,000	Pricing influenced by local policies

• Price pressures and value-based pricing models are increasingly influencing revenues.

---

Financial Trajectory Analysis

Historical Sales Data

Year	Sales (USD millions)	Growth Rate
2018	150	—
2019	182	21.3%
2020	210	15.4%
2021	240	14.3%
2022	280	16.7%

Source: AstraZeneca Annual Reports, 2022.

The trend reflects steady adoption, fueled by existing clinical data favoring TUDORZA PRESSAIR’s tolerability and convenience.

Forecasting Future Revenue

Based on current market trends, competitive positioning, and pipeline developments, an optimistic outlook estimates CAGR of 12-15% from 2023-2027.

Year	Predicted Sales (USD millions)	CAGR	Assumptions
2023	320		Continued growth, expanded geographic coverage
2024	370	15.6%	Entry into additional markets, enhanced reimbursement
2025	430	16.2%	Expanded indication support, switch from competitors
2026	500	16.3%	Patent protections, stable pricing
2027	580	16%	No major patent expiries

Factors Supporting Growth

• Expanding use in emerging markets (e.g., China, India)
• Increasing awareness and diagnosis rates
• Potential combination therapies and line extensions
• Strategic market expansion by AstraZeneca

Risks and Challenges

• Patent expiration and patent litigation
• Pricing pressures and health policy shifts
• Competition from newer inhaler technologies or biologics
• Patient adherence challenges

---

How Does TUDORZA PRESSAIR Compare with Competitors and Emerging Therapies?

Comparison Table

Attribute	TUDORZA PRESSAIR	Spiriva (Boehringer)	Anoro Ellipta (GSK)	ULAB Generic (regional)
Mechanism	LAMA	LAMA	LAMA/LABA	Varies
Dosing	Once daily	Once daily	Once daily	Varies
Delivery	Inhaler (pressurized powder)	Dry powder inhaler	Dry powder inhaler	Varies
Patent Status	Valid until ~2028	Expired	Patented until ~2030	Not applicable
Market Share (2022)	15%	22%	25%	38%

Emerging Therapeutics and Pipeline Products

• Dual-inhaler combinations (LAMA/LABA, LABA/ICS)
• Biologic therapies for COPD (e.g., PDE4 inhibitors)
• Device innovations for improved compliance

The competitive landscape demands continuous innovation and strategic positioning for TUDORZA PRESSAIR to maintain market share.

---

Regulatory and Policy Landscape

• FDA approval granted in 2012; expanded indications in subsequent years.
• EMA approvals in the EU follow similar timelines.
• Recent shifts toward value-based care and generics could impact pricing strategies.
• Regulatory pathways for biosimilars are evolving, with biosimilar inhalers potentially entering by 2028.

---

Strategic Considerations for Stakeholders

• For Investors: Monitor patent expirations, regional expansion, and pipeline developments.
• For Manufacturers: Focus on device improvements and combination formulations.
• For Payers: Engage in value-based reimbursement negotiations.
• For Clinicians: Advocate for tailored COPD management plans that include TUDORZA PRESSAIR based on evidence and patient preference.

---

Key Takeaways

• TUDORZA PRESSAIR is positioned as a vital player in the COPD inhaler market, with steady growth driven by demographic trends and clinical preference.
• Patent life until approximately 2028 offers a window for revenue optimization; imminent patent expiries necessitate strategic innovation.
• Competition remains fierce, with market leaders leveraging combination therapies and device advancements.
• Regulatory policies and reimbursement strategies significantly influence market trajectory.
• Emerging therapies and generics will challenge TUDORZA PRESSAIR, making innovation and market expansion crucial.

---

FAQs

1. When is TUDORZA PRESSAIR expected to face generic competition?
Patent protections are projected to expire around 2028, after which generic versions could enter the market, potentially impacting revenues.

2. How does TUDORZA PRESSAIR differentiate itself from competitors?
Its once-daily dosing, inhaler design, and targeted clinical profile provide smooth patient adherence and clinician preference.

3. Are there combination therapies involving TUDORZA PRESSAIR in development?
Yes. AstraZeneca and other companies are exploring combination inhalers (e.g., LAMA/LABA), which may influence TUDORZA’s market share upon approval.

4. Which emerging markets are key for TUDORZA PRESSAIR's expansion?
China, India, and Latin America are critical due to rising COPD prevalence and improving healthcare infrastructure.

5. What role do regulatory policies play in TUDORZA PRESSAIR’s future?
Stringent pricing controls, reimbursement negotiations, and expedited approval pathways could either restrict or accelerate its market penetration.

---

References

[1] WHO Global Health Estimates, 2022.

[2] AstraZeneca Annual Reports, 2018-2022.

[3] MarketResearch.com, COPD inhaler market forecast, 2022.

[4] FDA and EMA approval documents, 2012-2022.

[5] IQVIA data, global inhaler market share reports, 2022.

---

This detailed analysis offers a strategic lens into TUDORZA PRESSAIR’s market positioning and financial outlook, enabling stakeholders to make informed decisions amid shifting therapeutic and policy landscapes.